Overview
News
Technologies
Salaries
Products
People
Growth
Financials
News
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity's 46th Annual Growth
Read more
Report